WE研究:A型肉毒毒素能否让脑瘫儿童行走更轻松?一项随机对照试验的研究方案
该研究为随机、双盲、安慰剂对照、多中心试验,在挪威三个健康区域纳入96名4至17.5岁、粗大运动功能分类系统I和II级、转诊接受小腿肌肉单水平A型肉毒毒素注射的痉挛型脑瘫儿童,按1:1随机接受A型肉毒毒素(Botox®)或0.9%生理盐水注射,主要结局为注射后12周行走能量消耗的变化。
要点
- 纳入96名4至17.5岁痉挛型脑瘫儿童,随机接受A型肉毒毒素(Botox®)或0.9%生理盐水小腿肌肉注射。
- 主要结局为注射后12周行走能量消耗变化,次要结局包括步行能力、活动、移动任务表现与满意度及疼痛。
- 主要分析采用线性混合模型检验组间结局变化差异,招募于2015年9月开始。
核心结论
- 研究旨在确定小腿肌肉注射A型肉毒毒素是否使脑瘫儿童行走更轻松,假设可降低行走能量消耗、改善步行能力、增加习惯性身体活动、减轻疼痛并改善自我感知表现与满意度。
研究设计与样本
- 随机、双盲、安慰剂对照、多中心试验,在挪威三个健康区域临床环境中开展,纳入96名痉挛型脑瘫儿童,按年龄和研究中心的进行分层,分配比1:1。
- 纳入标准为年龄4至17.5岁、粗大运动功能分类系统I和II级、过去6个月未在下肢注射A型肉毒毒素、过去2年未行下肢矫形手术。
- 受试者随机接受小腿肌肉注射A型肉毒毒素(Botox®)或0.9%生理盐水,结局在基线及注射后4、12(主要终点)、24周评估。
主要发现
- 主要结局为行走能量消耗的变化,次要结局为步行能力变化、活动变化、移动任务中表现与满意度的感知变化及疼痛。
- 主要分析采用线性混合模型检验组间结局指标变化的差异。
关键数值与推荐
- 主要终点为注射后12周行走能量消耗的变化。
- 次要结局包括步行能力变化、活动变化、移动任务中表现与满意度的感知变化及疼痛。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intramuscular injections of botulinum toxin A (BoNT-A) have been a cornerstone in the treatment of spasticity for the last 20 years. In Norway, the treatment is now offered to two out of three children with spastic cerebral palsy (CP). However, despite its common use, the evidence for its functional effects is limited and inconclusive. The objective of this study is to determine whether BoNT-A makes walking easier in children with CP. We hypothesize that injections with BoNT-A in the calf muscles will reduce energy cost during walking, improve walking capacity, increase habitual physical activity, reduce pain and improve self-perceived performance and satisfaction. METHODS/DESIGN: This randomized, double-blinded, placebo-controlled, multicenter trial is conducted in a clinical setting involving three health regions in Norway. Ninety-six children with spastic CP, referred for single-level injections with BoNT-A in the calf muscles, will be invited to participate. Those who are enrolled will be randomized to receive either injections with BoNT-A (Botox®) or 0.9% saline in the calf muscles. Stratification according to age and study center will be made. The allocation ratio will be 1:1. Main inclusion criteria are (1) age 4 - 17.5 years, (2) Gross Motor Function Classification System levels I and II, (3) no BoNT-A injections in the lower limbs during the past 6 months and (4) no orthopedic surgery to the lower limbs during the past 2 years. The outcome measures will be made at baseline and 4, 12 (primary endpoint) and 24 weeks after injections. Primary outcome is change in energy cost during walking. Secondary outcomes are change in walking capacity, change in activity, perceived change in performance and satisfaction in mobility tasks, and pain. The primary analysis will use a linear mixed model to test for difference in change in the outcome measures between the groups. The study is approved by the Regional Ethical Committee and The Norwegian Medicines Agency. Recruitment started in September 2015. DISCUSSION: The evaluation of effect is comprehensive and includes objective standardized tests and measures on both impairment and activity level. Results are to be expected by spring 2019. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02546999 . Registered on 9 September 2015.
引用
- Brændvik SM, Roeleveld K, Andersen GL, et al. The WE-Study: does botulinum toxin A make walking easier in children with cerebral palsy?: Study protocol for a randomized controlled trial. Trials. 2017. PMID: 28166806. doi:10.1186/s13063-016-1772-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。